Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MAT.0000000000002332 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association Between Impella Device Type and Short-Term Prognosis in Patients with Acute Myocardial Infarction-Related Cardiogenic Shock Receiving ECPELLA Support.
Int Heart J
December 2024
Second Department of Internal Medicine, University of Toyama.
Article Synopsis
- * Among 996 patients analyzed, those using the Impella 5.0/5.5 had significantly lower 30-day mortality rates compared to those using the smaller Impella 2.5/CP devices.
- * The findings suggest that using the larger Impella 5.5 or upgrading from the smaller model could improve survival rates in patients with advanced AMI-CS on ECPELLA support.
ECPELLA in Advanced Cardiogenic Shock: Venting for Anyone?
ASAIO J
November 2024
From the The CardioVascular Center, Tufts Medical Center, Boston, Massachusetts.
Trends and outcomes of different mechanical circulatory support modalities for acute myocardial infarction associated cardiogenic shock in patients undergoing early revascularization.
Am Heart J Plus
October 2024
Department of Cardiology, Louisiana State University, Shreveport, LA, USA.
Article Synopsis
- The study investigates the outcomes of different Mechanical Circulatory Support (MCS) devices, specifically comparing ECMO and Impella, in patients with cardiogenic shock due to acute myocardial infarction (AMI-CS).
- Data from the national readmission database revealed that the majority of patients received Impella, while the ECMO group was generally younger with fewer health issues.
- Despite advances in MCS technologies, there was no significant change in mortality rates for AMI-CS between 2016 and 2020, and ECMO had higher adverse outcomes compared to Impella, indicating a need for further research.
ECPELLA Mixing Cloud on Computed Tomography Angiogram.
Anesthesiology
January 2025
Department of Critical Care Medicine, and Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Jacksonville, Florida.
Contemporary optimal therapeutic strategy with escalation/de-escalation of temporary mechanical circulatory support in patients with cardiogenic shock and advanced heart failure in Japan.
J Artif Organs
September 2024
Second Department of Internal Medicine, Toyama University, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan.
The utilization of temporary mechanical circulatory support (MCS) in the management of cardiogenic shock is experiencing a notable surge. Acute myocardial infarction remains the predominant etiology of cardiogenic shock, followed by heart failure. Recent findings from the DanGer Shock trial indicate that the percutaneous micro-axial flow pump support, in conjunction with standard care, significantly reduced 6-month mortality in patients with acute myocardial infarction-related cardiogenic shock compared to those receiving standard care alone.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!